Cannabis - Medical
•25 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (25)
%
| Company | Market Cap | Price |
|---|---|---|
|
International medical cannabis growth (Germany, EU-GMP facilities) supports Cannabis - Medical.
|
$1.89B |
$1.72
-14.43%
|
|
ZYN002 uses synthetic cannabidiol delivered as a transdermal gel, representing cannabis-based medical therapeutics in development.
|
$1.52B |
$26.54
-1.19%
|
|
Directly produces and sells regulated medical cannabis in core medical markets (e.g., Florida, Pennsylvania).
|
$1.46B |
$7.64
+5.67%
|
|
Medical cannabis operations and distribution (e.g., Peace Naturals in Israel/Canada).
|
$1.01B |
$2.63
-0.75%
|
|
Village Farms engages in medical cannabis production/export through international medical cannabis markets.
|
$371.84M |
$3.31
-9.81%
|
|
Aurora's core business is global medical cannabis cultivation, processing, and distribution, making Cannabis - Medical its primary direct product tag.
|
$290.85M |
$5.30
-12.11%
|
|
Strategic expansion into Germany's medical cannabis market via Remexian Pharma GmbH, indicating medical cannabis product supply and distribution.
|
$275.93M |
$3.43
-5.51%
|
|
Direct production and sale of medical cannabis products in Canada.
|
$253.71M |
$1.37
-13.84%
|
|
Produces medical cannabis products as part of its product portfolio.
|
$198.26M |
$1.91
-4.50%
|
|
Involvement in medical cannabis products and related production and distribution across states.
|
$180.71M |
$0.88
-0.68%
|
|
BLMH references medical cannabis products and services, indicating a medical cannabis revenue stream.
|
$162.23M |
$0.70
|
|
Medical cannabis category in medical markets (cultivation/processing and medical dispensary footprint).
|
$120.18M |
$0.61
+0.05%
|
|
Provides medical cannabis products as part of its vertical integration and product lineup.
|
$80.81M |
$0.40
-4.76%
|
|
VidaCann acquisition and Florida MMTC license, cultivation and processing capabilities indicate a medical cannabis production/distribution line.
|
$77.76M |
$0.22
-6.14%
|
|
Direct medical cannabis product line and physician-dispensed therapies.
|
$72.92M |
$1.60
-4.76%
|
|
Operates medical cannabis products in markets where medical cannabis is offered, contributing to core product revenue.
|
$53.25M |
$0.17
-2.88%
|
|
Medical cannabis/cannabinoid therapeutics category for disease indication and treatment.
|
$33.48M |
$0.40
-4.29%
|
|
Day Three Labs cannabis technology aligns with Cannabis - Medical.
|
$33.38M |
$1.34
-1.47%
|
|
MIRA-55 is described as a CB2-selective oral cannabinoid molecule, aligning with Cannabis - Medical category.
|
$21.32M |
$1.26
-6.67%
|
|
IHL-42X uses dronabinol (cannabinoid) in its formulation, a cannabis-based medical therapy.
|
$11.53M |
$0.39
-9.33%
|
|
Company aims to develop specialized medical cannabis compounds and conduct related clinical research, fitting Cannabis - Medical.
|
$5.44M |
$0.04
-10.02%
|
|
Cannabis - Medical presence via tenants in regulated cannabis real estate.
|
$5.37M |
$0.45
+1.36%
|
|
Core product offering is medical cannabis products produced and distributed for medical use.
|
$4.31M |
$1.93
-4.46%
|
|
Cannabis - Medical: CBDY targets the medical cannabis market in Canada.
|
$1.05M |
$0.00
|
|
Cannabis cultivation focus within Canada (medical cannabis category).
|
$905027 |
$2.18
-5.22%
|
Loading industry metrics...
Loading comparison data...
